JP2020533971A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533971A5
JP2020533971A5 JP2020511477A JP2020511477A JP2020533971A5 JP 2020533971 A5 JP2020533971 A5 JP 2020533971A5 JP 2020511477 A JP2020511477 A JP 2020511477A JP 2020511477 A JP2020511477 A JP 2020511477A JP 2020533971 A5 JP2020533971 A5 JP 2020533971A5
Authority
JP
Japan
Prior art keywords
fusion protein
cells
soluble
protein complex
soluble fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020511477A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533971A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/048365 external-priority patent/WO2019046313A1/en
Publication of JP2020533971A publication Critical patent/JP2020533971A/ja
Publication of JP2020533971A5 publication Critical patent/JP2020533971A5/ja
Withdrawn legal-status Critical Current

Links

JP2020511477A 2017-08-28 2018-08-28 Il−15をベースとするil−7及びil−21への融合物 Withdrawn JP2020533971A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762551218P 2017-08-28 2017-08-28
US62/551,218 2017-08-28
PCT/US2018/048365 WO2019046313A1 (en) 2017-08-28 2018-08-28 IL-15 BASED FUSIONS WITH IL-7 AND IL-21

Publications (2)

Publication Number Publication Date
JP2020533971A JP2020533971A (ja) 2020-11-26
JP2020533971A5 true JP2020533971A5 (ja�@�@) 2021-10-07

Family

ID=65526059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020511477A Withdrawn JP2020533971A (ja) 2017-08-28 2018-08-28 Il−15をベースとするil−7及びil−21への融合物

Country Status (8)

Country Link
US (4) US11161890B2 (ja�@�@)
EP (1) EP3676289B1 (ja�@�@)
JP (1) JP2020533971A (ja�@�@)
KR (1) KR20200090742A (ja�@�@)
CN (1) CN111655716B (ja�@�@)
AU (1) AU2018323455B2 (ja�@�@)
CA (1) CA3074635A1 (ja�@�@)
WO (1) WO2019046313A1 (ja�@�@)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743249B (zh) * 2007-05-11 2017-08-08 阿尔托生物科学有限公司 融合分子与il‑15变异体
CN110199017A (zh) * 2017-01-20 2019-09-03 国立大学法人京都大学 CD8α+β+细胞毒性T细胞的制备方法
KR102867975B1 (ko) 2017-03-06 2025-10-14 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
JP2020533971A (ja) 2017-08-28 2020-11-26 アルター・バイオサイエンス・コーポレーション Il−15をベースとするil−7及びil−21への融合物
WO2020037120A1 (en) * 2018-08-16 2020-02-20 Nantbio, Inc. Il7-il15 txm compositions and methods
CN120365435A (zh) 2018-08-30 2025-07-25 免疫生物公司 单链嵌合多肽和多链嵌合多肽以及其用途
EP3843788A1 (en) 2018-08-30 2021-07-07 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CN112996805A (zh) 2018-08-30 2021-06-18 Hcw生物科技公司 多链嵌合多肽和其用途
GB201818816D0 (en) * 2018-11-19 2019-01-02 Synpromics Ltd Regulatory nucleic acid sequences
CN111825770B (zh) * 2019-04-16 2023-06-09 成都医学院 长效白介素21-Fc融合蛋白及其用途
JP7713393B2 (ja) * 2019-06-21 2025-07-25 イミュニティーバイオ インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
GB201909144D0 (en) 2019-06-25 2019-08-07 Autolus Ltd Culture medium
AU2019456283B2 (en) * 2019-07-08 2023-06-08 Immunitybio, Inc. Mononuclear cell derived NK cells
US11453862B2 (en) 2019-07-08 2022-09-27 Immunitybio, Inc. Mononuclear cell derived NK cells
US20210061871A1 (en) * 2019-08-29 2021-03-04 Nantbio, Inc. Modified N-810 and Methods Therefor
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
KR20220140535A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
US12115191B2 (en) 2020-02-11 2024-10-15 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
EP4103599A1 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of activating regulatory t cells
EP4143231A1 (en) 2020-04-29 2023-03-08 HCW Biologics, Inc. Anti-cd26 proteins and uses thereof
WO2021247003A1 (en) * 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
EP4157460A1 (en) * 2020-06-01 2023-04-05 HCW Biologics, Inc. Methods of treating aging-related disorders
GB202008957D0 (en) 2020-06-12 2020-07-29 Autolus Ltd Culture medium
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
IL308609A (en) 2021-05-19 2024-01-01 Asher Biotherapeutics Inc IL-21 polypeptides and target constructs
WO2022260849A1 (en) 2021-06-09 2022-12-15 Nant Holdings Ip, Llc Methods and systems for producing a protein of interest in a plant
US20250051414A1 (en) * 2021-06-30 2025-02-13 The Regents Of The University Of California Altering cytokine specificity through binding valency
CN113549158B (zh) * 2021-07-19 2022-10-21 广州百暨基因科技有限公司 包含突变型il15以及嵌合抗原受体的融合蛋白
EP4507711A1 (en) 2022-04-13 2025-02-19 ImmunityBio, Inc. Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
CN119546343A (zh) * 2022-04-27 2025-02-28 亚设生物治疗公司 细胞因子融合蛋白与cd8抗原结合分子的组合
US20260048099A1 (en) * 2022-08-16 2026-02-19 The United States Of America, As Represented By The Secretary, Deparment Of Health And Human Service Synergistic interactions for improved cancer treatment
KR20250160456A (ko) * 2023-03-23 2025-11-13 길리애드 사이언시즈, 인코포레이티드 Tnf 슈퍼패밀리 멤버 면역사이토카인 및 이의 용도
CN117186243B (zh) * 2023-07-26 2025-08-19 四川三优康生物技术有限公司 猪白细胞介素15,21和23共表达生物制剂材料及应用
WO2025064822A2 (en) * 2023-09-20 2025-03-27 Factor Bioscience Inc. Cells and methods for engineering cells with persistent transgene expression
CN117050178B (zh) * 2023-10-13 2024-01-12 北京百普赛斯生物科技股份有限公司 特异性检测il-7的抗体及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8507A (en) 1851-11-11 petess
US222A (en) 1837-06-10 Truss for the retention and radical cure qe hernia
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
AU5098393A (en) 1992-08-14 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant toxin with increased half-life
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5534592A (en) 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
KR101131297B1 (ko) 2003-11-10 2012-03-30 알토 바이오사이언스 코포레이션 가용성 티씨알 분자 및 이용 방법
CN101743249B (zh) 2007-05-11 2017-08-08 阿尔托生物科学有限公司 融合分子与il‑15变异体
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
US8507222B2 (en) * 2010-09-21 2013-08-13 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
EP3359157A4 (en) * 2015-10-06 2019-05-15 The Wistar Institute Of Anatomy And Biology METHOD AND COMPOSITIONS FOR THE TREATMENT OF METASTASIVE AND REFRACTORY CANCER DISEASES AND TUMORS
EP4613776A3 (en) 2016-10-21 2025-11-26 Altor BioScience Corporation Multimeric il-15-based molecules
JP2020533971A (ja) 2017-08-28 2020-11-26 アルター・バイオサイエンス・コーポレーション Il−15をベースとするil−7及びil−21への融合物

Similar Documents

Publication Publication Date Title
JP2020533971A5 (ja�@�@)
US10428119B2 (en) Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes
AU2007271398B2 (en) Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
JP2023123877A (ja) 養子細胞療法のための腫瘍浸潤リンパ球
JP2020508691A5 (ja�@�@)
CN110198737A (zh) 靶向psma的三特异性蛋白质及使用方法
JP2005520853A (ja) 蛋白質ワクチン接種の有効なアジュバントとしての抗体融合蛋白質
AU2012268013A1 (en) Pseudomonas exotoxin A with less immunogenic T cell and/or B cell epitopes
JP2019520309A (ja) 炎症性免疫サイトカインおよびキメラ抗原受容体(car)−t細胞を含む併用治療
Debets et al. Cytokine antagonists and their potential therapeutic use
JP2022502015A5 (ja�@�@)
US20070003514A1 (en) Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
KR102578682B1 (ko) Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells)
CN119264269A (zh) 结合cd19的嵌合抗原受体及其用途
Selinsky et al. Soluble tumor necrosis factor receptor type I enhances tumor development and persistence in vivo
CA3198822A1 (en) Multi-functional and multi-valent interleukin-tgf-beta receptor fusion polypeptides
WO2021092719A1 (zh) 一种靶向抗原特异性t细胞诱导其向记忆干性细胞分化的融合蛋白
EP1448603A2 (en) Fusion proteins containing tlp peptides
RU2024116904A (ru) Улучшенные антигенсвязывающие рецепторы
US20090148440A1 (en) Antibodies against interleukin-22 binding protein and its uses for the treatment of metabolic disorders
CN119367516A (zh) 一种免疫调节因子组合物及其应用
KR101286065B1 (ko) 항-Her-2/neu 키메라 면역 수용체를 발현하는 사이토카인 유도 살해세포, 이를 포함하는 약제학적 조성물 및 이를 이용한 종양 치료 방법
WO2024099990A1 (en) TGF-ß SWITCH RECEPTOR CAR T CELLS
KR20260056925A (ko) 종양 표적의 키메라 항원 수용체를 포함하는 면역세포 및 이의 용도
JP2024527963A5 (ja�@�@)